addition of venetoclax to lenalidomide and rituximab in patients with untreated mcl
Published 1 year ago • 133 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
2:22
venetoclax, lenalidomide and rituximab in r/r mcl
-
1:12
traverse: acalabrutinib venetoclax and rituximab for treatment-naïve mcl
-
1:28
a long-term analysis of lenalidomide and rituximab for the treatment of cll
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
2:25
update from murano trial: venetoclax-rituximab leads to slower clonal growth rate in cll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
5:00
diagnosing and treating al amyloidosis: a 2020 update from dr morie gertz
-
11:36
my six-hour rituxan infusion for autoimmune disease
-
9:25
mgus diagnosis: a step-by-step approach
-
2:09
overview of the cll13 trial: replacing chemotherapy with venetoclax-containing regimens
-
2:04
time-limited venetoclax-rituximab in r/r cll patients previously exposed to btki’s
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:29
combo of rg6146/venetoclax/rituximab for r/r dlbcl: initial data
-
1:01
recent and future changes in the landscape of aml: the addition of venetoclax and mrd eradication
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:02
maintenance therapy following treatment for amyloidosis
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
3:37
sympatico: ibrutinib combined with venetoclax in patients with r/r mcl